Drug Trial Radar · NCT04848688
Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Last checked: Nov 19, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
332
Actual
Start
Feb 5, 2022
Primary completion
Jul 17, 2022
Study completion Jul 17, 2022
Sponsor
- Lead sponsor
- Jennifer KeiserAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Centre for Parasitology, Entomology and Malaria Control, Cambodia
- First posted
- Apr 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is an extension to the study StrongMoxi NCT04056325 and entails modifications based on the outcome of NCT04056325 part A. The study is a phase 3, double-blinded and randomized clinical trial conducted in Cambodia. It aims at providing evidence on efficacy, safety and pharmacokinetic measures of 8 mg of moxidectin compared to 200 μg/kg ivermectin in adults infected with S. stercoralis. The efficacy of the treatment will be assessed by collecting three stool samples once per-treatment and once 21-28 days post-treatment. The stool samples will be analyzed by a quantitative duplicate Baermann assay.
Conditions
- Strongyloides Stercoralis Infection
Interventions
Moxidectin 2 mgDrug
Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
Ivermectin 3 mgDrug
Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
PlaceboDrug
Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cure Rate Against Strongyloides StercoralisTime frame: 14-21 days after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Centre for Parasitology, Entomology and Malaria Control
Phnom Penh, Cambodia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.